Table 1.
Patient Demographics, Tumor Histology and Laboratory Results (N = 62)
| Characteristic | Number of patients (%) |
|---|---|
| Gender | |
| Female | 25 (40.3) |
| Male | 37 (59.6) |
| Age: 63.2 ± 13.1 y, 16-89a | |
| <45 | 3 (4.8) |
| >45 | 59 (95.1) |
| Histology | |
| Follicular | 4 (6.4) |
| Hurthle | 14 (22.5) |
| Papillary | |
| Classical Papillary Thyroid Cancer | 37 (59.6) |
| Insular | 1 (1.6) |
| Macrofollicular Variant | 1 (1.6) |
| Tall Cell Variant | 5 (8.0) |
| Baseline Thyroglobulin [ng/mL] | |
| <10 | 5 (8.0) |
| 10-100 | 10 (16.1) |
| 100-1000 | 17 (27.4) |
| >1000 | 16 (25.8) |
| Anti-thyroglobulin antibodies present | 12 (19.5%) |
| Missing | 2 (3.2%) |
| Thyroglobulin Doubling Time (TgDT) | |
| Minimum TgDT: 1.8 Months | |
| Maximum TgDT: 62.9 Months | |
| TgDT between 0 and 6 months | 17 (27.4) |
| TgDT between 6 and 12 months | 17 (27.4) |
| TgDT between 12 and 24 months | 10 (16.1) |
| TgDT>24 months | 3 (4.8) |
| Anti-thyroglobulin antibodies present | 12 (19.5%) |
| Negative TgDT due to local treatmentb | 3 (4.8%) |
| Stage at Diagnosis | |
| I | 3 (4.8) |
| II | 3 (4.8) |
| III | 18 (29.0) |
| IVA | 13 (20.9) |
| IVB | 6 (9.6) |
| IVC | 19 (30.6) |
| Prior Treatments | |
| Surgery, RAI | 42 (67.7) |
| Surgery, RAI, Chemo | 2 (3.2) |
| Surgery, RAI, EBRT | 17 (27.4) |
| Surgery, RAI, Chemotherapy, EBRT | 1 (1.6) |
| Site of Metastatic Disease | |
| Regional Lymph Node | 27 (43.5) |
| Distant Lymph Node | 19 (30.6) |
| Lung | 44 (70.9) |
| Bone | 17 (27.4) |
| Other | 2 (3.2) |
|
| |
| Results of Initial PET Scan | |
| Regional Mets | 6 (9.6) |
| Distant Mets | 17 (27.4) |
| Both | 39 (62.9) |
a
Presented as mean ± SD, range
b
Surgical resection of cervical metastases resulted in negative TgDT
RAI, Radioiodine; EBRT, External Beam Radiation Therapy